PDS Historical Income Statement
| PDSB Stock | USD 3.12 0.13 4.00% |
Historical analysis of PDS Biotechnology income statement accounts such as Research Development of 18.8 M, Total Operating Expenses of 30.6 M, Income Tax Expense of 1.5 M or Interest Income of 3 M can show how well PDS Biotechnology Corp performed in making a profits. Evaluating PDS Biotechnology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of PDS Biotechnology's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining PDS Biotechnology Corp latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether PDS Biotechnology Corp is a good buy for the upcoming year.
PDS |
About PDS Income Statement Analysis
PDS Biotechnology Corp Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to PDS Biotechnology shareholders. The income statement also shows PDS investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
PDS Biotechnology Income Statement Chart
Add Fundamental
Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of PDS Biotechnology Corp. It is also known as PDS Biotechnology overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Total Operating Expenses
The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.Tax Provision
The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.Most accounts from PDS Biotechnology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into PDS Biotechnology Corp current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. At present, PDS Biotechnology's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Income Tax Expense is expected to grow to about 1.5 M, whereas Depreciation And Amortization is forecasted to decline to about 54.5 K.
| 2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 4.3K | 1.3M | 4.2M | 4.4M | Depreciation And Amortization | 246.4K | 49.1K | 57.3K | 54.5K |
PDS Biotechnology income statement Correlations
Click cells to compare fundamentals
PDS Biotechnology Account Relationship Matchups
High Positive Relationship
High Negative Relationship
PDS Biotechnology income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 4.3M | 176.3K | 246.4K | 49.1K | 57.3K | 54.5K | |
| Interest Expense | 33.6K | 33.0K | 4.3K | 1.3M | 4.2M | 4.4M | |
| Selling General Administrative | 11.0M | 7.0M | 10.2M | 12.2M | 15.0M | 11.7M | |
| Other Operating Expenses | 17.1M | 14.9M | 21.4M | 41.7M | 43.0M | 30.6M | |
| Operating Income | (21.0M) | (14.9M) | (21.4M) | (41.7M) | (43.0M) | (45.2M) | |
| Ebit | (21.0M) | (15.0M) | (21.7M) | (40.8M) | (43.0M) | (45.2M) | |
| Research Development | 6.1M | 7.9M | 11.3M | 29.4M | 27.8M | 18.8M | |
| Ebitda | (16.7M) | (14.8M) | (21.4M) | (40.7M) | (43.0M) | (45.1M) | |
| Total Operating Expenses | 17.1M | 14.9M | 21.4M | 41.7M | 43.0M | 30.6M | |
| Income Before Tax | (7.4M) | (14.8M) | (21.4M) | (42.1M) | (44.3M) | (46.6M) | |
| Total Other Income Expense Net | 13.7M | 55.0K | 4.3K | (381.3K) | (1.3M) | (1.2M) | |
| Net Income | (7.0M) | (14.8M) | (16.9M) | (40.9M) | (42.9M) | (45.1M) | |
| Income Tax Expense | (381.5K) | (135.7K) | (4.5M) | (1.2M) | 1.4M | 1.5M | |
| Tax Provision | (2.8M) | (381.5K) | (4.5M) | (1.2M) | (1.4M) | (1.5M) | |
| Interest Income | 353.5K | 55.0K | 4.3K | 935.2K | 2.8M | 3.0M | |
| Net Income Applicable To Common Shares | (7.0M) | (14.8M) | (16.9M) | (40.9M) | (36.8M) | (34.9M) | |
| Net Interest Income | 319.9K | 55.0K | 4.3K | (381.3K) | (1.1M) | (1.2M) | |
| Net Income From Continuing Ops | (7.0M) | (14.8M) | (16.9M) | (40.9M) | (51.2M) | (53.7M) | |
| Reconciled Depreciation | 98.4K | 15.6K | 5.4K | 86.0 | 12.6K | 12.0K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| MSFT | Microsoft | |
| F | Ford Motor | |
| CRM | Salesforce |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PDS Biotechnology Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.